36 results about "Middle East respiratory syndrome coronavirus" patented technology

The invention discloses a subunit coronavirus vaccine for dimerization-based receptor binding domains and belongs to the technical field of medicine. A baculovirus expresses RBD (receptor binding domain (E367-Y606) of MERS-CoV (middle east respiratory syndrome coronavirus) protein and RBD (R294-F515) of SARS-CoV (severe acute respiratory syndrome coronavirus) in insect cells, the RBDs may form a dimer through cysteine residue at 603 of S (spike) protein or form a dimer through cysteine residue at 512 of the S protein, and purified RBD protein dimer and monomer are used respectively to immunize Bald/c mice. The dimerized RBDs have the advantages that the defect that RBD monomers have poor immunogenicity is overcome and the generation of neutralizing antibodies in against MERS-CoV is increased greatly.

The invention provides a fluorescent RT-RAA (Reverse Transcription Recombinase Aid Amplification) primer for detecting MERS-CoV (Middle East Respiratory Syndrome Coronavirus), a fluorescent probe andapplication of the fluorescent RT-RAA primer and the fluorescent probe in detecting the MERS-CoV. The fluorescent RT-RAA primer and the fluorescent probe, disclosed by the invention, are capable of quickly and qualitatively detecting the MERS-CoV in a throat swab sample, detection can be carried out under the normal temperature of 39 DEG C, a diagnosis result can be obtained within 20 minutes, andthe detection time is greatly shortened; the fluorescent RT-RAA primer and the fluorescent probe are stronger in specificity and higher in sensitivity, quick diagnosis and whole-process monitoring onan epidemic situation can be completely met, and time is bought for early diagnosing and early treating the epidemic situation, reducing a case fatality rate and controlling the epidemic situation.

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

The invention relates to the field of biomedicine, in particular to application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as a deubiquitinating enzyme and interferon inhibitor. The invention provides a novel deubiquitinating enzyme and interferon inhibitor; the new understanding of the functionality of human coronavirus proteinase can be expanded; theoretical basis can be provided for the research on coronavirus and host antiviral natural immunization and the research on antiviral drugs using viral proteinase as a target.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.

A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.

Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.

Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

The present invention belongs to the technical field of biology, and relates to a de-fucosylated fully humanized monoclonal antibody for Middle East Respiratory Syndrome Coronavirus (MERS-CoV), an antigen binding fragment, and applications thereof, wherein the de-fucosylated fully humanized monoclonal antibody is mainly characterized in that the de-fucosylated fully humanized monoclonal antibody has an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effect, wherein the effect comprises cleaving the cells expressing MERS-CoV S protein. The present invention further relates to a method for making cells express the de-fucosylated MERS-CoV fully humanized monoclonal antibody by inhibiting fucosyltransferase activity. According to the present invention, by using the antibody, the Middle Eastern respiratory syndrome can be clinically prevented or treated.

The invention relates to application of teicoplanin in preparation of drugs for MERS-CoV (Middle East respiratory syndrome coronavirus). According to the application, teicoplanin compounds have the effect of treating the MERS-CoV in vitro.

The invention relates to application of glucocorticoid in preparation of a medicine for treating and/or preventing respiratory virus infection. The respiratory viruses are selected from SARS-CoV virus, SARS-CoV-2 virus, Middle East respiratory syndrome coronavirus, influenza virus, measles virus, parotitis virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Hendea virus, Nipie virus, rubella virus, rhinovirus, adenovirus, reovirus, coxsackie virus and ECHO virus.

The invention discloses a RBD (receptor binding domain) segment in a MERS-CoV (Middle East respiratory syndrome coronavirus) membrane protein and a coding gene and application thereof. 1, A protein is as follows: (a) a protein comprising 4th to 243th-site amino acid residues from N terminal of a sequence 1 in a sequence table; or (b) a protein comprising 1th to 243th-site amino acid residues from the N terminal of the sequence 1 in the sequence table; or (c) a protein comprising 4 to 249-site amino acid residues from the N terminal of the sequence 1 in the sequence table; or (d) a protein shown as the sequence 1 of the sequence table. The invention finds that MERS-CoV may have a potential receptor binding domain (Receptor Binding Domain, RBD), and in-depth studies on the RBD help to discover a key target blocking the MERS-CoV invasion, and have important theory reference values to research and development of treatment drugs and preventive vaccines of the MERS-CoV.